SNCA and Parkinson disease: Further genetic, epidemiological, and experimental evidence supports the notion that, while a lifelong α-synuclein elevation is itself capable of triggering PD-like pathology and clinical parkinsonism, more transient and/or less pronounced protein increases also bear pathogenetic implications.